$VCEL News

Vericel Corporation 2026 Q1 - Results - Earnings Call Presentation

Vericel Corp (NASDAQ:VCEL): A Prime Example of Affordable Growth

HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $70

Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript

Vericel Corp (NASDAQ:VCEL) Smashes Q1 Estimates, Raises Full-Year Outlook as MACI and Burn Care Surge

Vericel Raises FY2026 Sales Guidance from $316.000M-$326.000M to $326.000M-$336.000M vs $323.377M Est

Vericel Q1 EPS $(0.12) Beats $(0.15) Estimate, Sales $68.425M Beat $63.638M Estimate

Vericel Corp (NASDAQ:VCEL) Presents a Compelling Growth and Technical Setup Opportunity

Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026

Truist Securities Maintains Buy on Vericel, Lowers Price Target to $42

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid

Vericel Corp. Awarded $196.8M HHS BARDA Contract For NonSurgical Debridement, Research And Development In Biotechnology (Except Nanobiotechnology)

Vericel Corp (NASDAQ:VCEL) Emerges as a Top Affordable Growth Pick

What Makes Vericel Corporation (VCEL) an Investment Bet?

Will FDA Approval of Burlington MACI Manufacturing Shift Vericel's (VCEL) Long-Term Growth Narrative

FDA MACI Approval Tests Vericel’s Capacity Plans And Growth Story

Vericel Corporation (VCEL) Secures FDA Approval for Commercial Manufacturing of MACI

Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility

Vericel Receives FDA Approval For MACI Manufacturing At Facility In Burlington, Mass